Literature DB >> 26989657

Clinical Characteristics of Patients with Cryptogenic Hepatocellular Carcinoma in a Hepatitis B Virus-Endemic Area.

Hee-Won Kwak1, Joong-Won Park1, Young Hwan Koh1, Ju Hee Lee1, Ami Yu2, Byung-Ho Nam2.   

Abstract

OBJECTIVES: Chronic hepatitis B virus (HBV) infection is the most common cause of hepatocellular carcinoma (HCC) in South Korea, but a high prevalence of metabolic diseases may result in increases in the incidence of cryptogenic HCC (cHCC). We studied characteristics of the cHCC in a single-center cohort.
METHODS: A cohort of 1,784 HCC patients newly diagnosed and treated at the National Cancer Center, Korea, between 2004 and 2009 was reviewed and analyzed.
RESULTS: The cause of HCC was categorized as cHCC, HBV, hepatitis C virus (HCV), or alcohol. Overall, 162 (9.1%) patients of the HCC cohort had cHCC, and their mean age was 61.9 years. The median survival of cHCC patients was 24.7 months, which was the second shortest among the four groups after HBV HCC. cHCC patients had the largest tumor size (mean 7.4 cm) and the second highest proportion of poor prognostic factors such as the proportion of poorly defined tumors and extrahepatic spread in imaging studies. cHCC patients had better survival than HBV HCC patients according to multivariate analysis. Among cHCC patients, 137 (84.6%) had anti-HBc IgG antibodies, but this sub-group had different clinical features to those of HBV HCC patients. The body mass index (BMI) and hyperglycemia and hypercholesterolemia levels in cHCC patients were similar to those in HCV and alcoholic HCC patients.
CONCLUSIONS: Anti-HBc IgG antibodies were present in most cHCC patients, but cHCC patients had better survival than HBV HCC patients on multivariate analysis. However, cHCC patients had a larger mean tumor size and more aggressive tumor characteristics than HCV HCC or alcoholic HCC patients did. It is hoped that this study will contribute to a better understanding of cHCC in HBV-endemic areas.

Entities:  

Keywords:  Anti-HBc antibodies; Cryptogenic; Hepatocellular carcinoma; Non-B non-C non-alcohol; Non-alcoholic fatty liver disease

Year:  2015        PMID: 26989657      PMCID: PMC4789902          DOI: 10.1159/000367756

Source DB:  PubMed          Journal:  Liver Cancer        ISSN: 1664-5553            Impact factor:   11.740


  43 in total

Review 1.  Nonalcoholic fatty liver disease.

Authors:  Leon A Adams; Keith D Lindor
Journal:  Ann Epidemiol       Date:  2007-08-28       Impact factor: 3.797

2.  Non-alcoholic fatty liver disease in the Asia-Pacific region: definitions and overview of proposed guidelines.

Authors:  Shivakumar Chitturi; Geoffrey C Farrell; Etsuko Hashimoto; Toshiji Saibara; George K K Lau; José D Sollano
Journal:  J Gastroenterol Hepatol       Date:  2007-06       Impact factor: 4.029

3.  Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008.

Authors:  Zobair M Younossi; Maria Stepanova; Mariam Afendy; Yun Fang; Youssef Younossi; Hesham Mir; Manirath Srishord
Journal:  Clin Gastroenterol Hepatol       Date:  2011-03-25       Impact factor: 11.382

4.  Relative etiological role of prior hepatitis B virus infection and nonalcoholic fatty liver disease in the development of non-B non-C hepatocellular carcinoma in a hepatitis B-endemic area.

Authors:  Eun Ju Cho; Min Sun Kwack; Eun Sun Jang; Su Jong You; Jeong-Hoon Lee; Yoon Jun Kim; Jung-Hwan Yoon; Hyo-Suk Lee
Journal:  Digestion       Date:  2011-12-02       Impact factor: 3.216

5.  Difference in malignancies of chronic liver disease due to non-alcoholic fatty liver disease or hepatitis C in Japanese elderly patients.

Authors:  Yasuji Arase; Mariko Kobayashi; Fumitaka Suzuki; Yoshiyuki Suzuki; Yusuke Kawamura; Norio Akuta; Norihiro Imai; Masahiro Kobayashi; Hitomi Sezaki; Naoki Matsumoto; Satoshi Saito; Tetsuya Hosaka; Kenji Ikeda; Hiromitsu Kumada; Yuki Ohmoto; Kazuhisa Amakawa; Shiun Dong Hsieh; Kyoko Ogawa; Maho Tanabe; Hiroshi Tsuji; Tetsuro Kobayashi
Journal:  Hepatol Res       Date:  2011-12-19       Impact factor: 4.288

6.  Prognosis of hepatocellular carcinoma: the BCLC staging classification.

Authors:  J M Llovet; C Brú; J Bruix
Journal:  Semin Liver Dis       Date:  1999       Impact factor: 6.115

Review 7.  Hepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menace.

Authors:  György Baffy; Elizabeth M Brunt; Stephen H Caldwell
Journal:  J Hepatol       Date:  2012-02-09       Impact factor: 25.083

8.  Clinical outcomes of a cohort series of patients with hepatocellular carcinoma in a hepatitis B virus-endemic area.

Authors:  Hee-Won Kwak; Joong-Won Park; Byung-Ho Nam; Ami Yu; Sang Myung Woo; Tae Hyun Kim; Seong Hoon Kim; Young Hwan Koh; Hyun Beom Kim; Sang Jae Park; Woo Jin Lee; Eun Kyung Hong; Chang-Min Kim
Journal:  J Gastroenterol Hepatol       Date:  2014-04       Impact factor: 4.029

9.  Risk factors for hepatocellular carcinoma among patients with chronic liver disease.

Authors:  H Tsukuma; T Hiyama; S Tanaka; M Nakao; T Yabuuchi; T Kitamura; K Nakanishi; I Fujimoto; A Inoue; H Yamazaki
Journal:  N Engl J Med       Date:  1993-06-24       Impact factor: 91.245

Review 10.  Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review.

Authors:  Donna L White; Fasiha Kanwal; Hashem B El-Serag
Journal:  Clin Gastroenterol Hepatol       Date:  2012-10-04       Impact factor: 11.382

View more
  7 in total

1.  Comparison of Hepatocellular Carcinoma in Patients with Cryptogenic Versus Hepatitis B Etiology: A Study of 1079 Cases Over 3 Decades.

Authors:  Zhong-Hong Liew; George Boon-Bee Goh; Ying Hao; Pik-Eu Chang; Chee-Kiat Tan
Journal:  Dig Dis Sci       Date:  2018-10-16       Impact factor: 3.199

2.  Non-B, Non-C Hepatocellular Carcinoma in an HBV- and HCV-Endemic Area: A Community-Based Prospective Longitudinal Study.

Authors:  Te-Sheng Chang; Nien-Tzu Hsu; Shu-Chuan Chen; I-Lin Hsu; Mei-Hsuan Lee; Sheng-Nan Lu
Journal:  Viruses       Date:  2022-05-07       Impact factor: 5.818

3.  Long-Term Prognostic Factors after Hepatic Resection for Hepatitis C Virus-Related Hepatocellular Carcinoma, with a Special Reference to Viral Status.

Authors:  Masaki Koda; Shogo Tanaka; Shigekazu Takemura; Hiroji Shinkawa; Masahiko Kinoshita; Genya Hamano; Tokuji Ito; Norifumi Kawada; Toshihiko Shibata; Shoji Kubo
Journal:  Liver Cancer       Date:  2018-03-13       Impact factor: 11.740

4.  Noncirrhotic hepatocellular carcinoma: etiology and occult hepatitis B virus infection in a hepatitis B virus-endemic area.

Authors:  Chang Woo Shim; Joong-Won Park; So Hee Kim; Jin Sook Kim; Bo Hyun Kim; Sung Hoon Kim; Eun Kyung Hong
Journal:  Therap Adv Gastroenterol       Date:  2017-05-22       Impact factor: 4.409

5.  Significant symptoms alleviation and tumor volume reduction after combined simultaneously integrated inner-escalated boost and volumetric-modulated arc radiotherapy in a patient with unresectable bulky hepatocellular carcinoma: A care-compliant case report.

Authors:  Young-Hsiang Lin; Shih-Kai Hung; Wen-Yen Chiou; Moon-Sing Lee; Bing-Jie Shen; Liang-Cheng Chen; Dai-Wei Liu; Wei-Ta Tsai; Po-Hao Lin; Yi-Ting Shih; Feng-Chun Hsu; Shiang-Jiun Tsai; Michael W Y Chan; Hon-Yi Lin
Journal:  Medicine (Baltimore)       Date:  2016-08       Impact factor: 1.889

6.  Potential etiology, prevalence of cirrhosis, and mode of detection among patients with non-B non-C hepatocellular carcinoma in Korea.

Authors:  Jihye Kim; Wonseok Kang; Dong Hyun Sinn; Geum-Youn Gwak; Yong-Han Paik; Moon Seok Choi; Joon Hyeok Lee; Kwang Cheol Koh; Seung Woon Paik
Journal:  Korean J Intern Med       Date:  2019-06-17       Impact factor: 2.884

7.  Effects of Positive Hepatitis B Core Antibody and Metabolic Disorders in Hepatocellular Carcinoma in an Endemic Area of Hepatitis B Virus.

Authors:  Hae Lim Lee; Si Hyun Bae; Jaejun Lee; Pil Soo Sung; Sung Won Lee; Jeong Won Jang; Jungmin Lee; Jong Young Choi; Nam Ik Han; Seung Kew Yoon
Journal:  Cancer Control       Date:  2021 Jan-Dec       Impact factor: 3.302

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.